European women's preference for osteoporosis treatment: Influence of clinical effectiveness and dosing frequency

Current Medical Research and Opinion

Volumn 22, Issue 12, 2006, Pages 2375-2381

  Keen, Richard ^a   Jodar, Esteban ^b   Iolascon, Giovanni ^c   Kruse, Hans Peter ^d   Varbanov, Alex ^e   Mann, Birgit ^e   Gold, Deborah T ^f  

^a ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Osteoporosezentrum Hamburg Neuer Wall   (Germany)

^e PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bisphosphonates; Compliance; Fracture efficacy; Hip Fracture; Non Vertebral fracture; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; CONFERENCE PAPER; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; EUROPE; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; RISK FACTOR; SPINE FRACTURE;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; EUROPE; FEMALE; HUMANS; INTERVIEWS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PATIENT SATISFACTION;

EID: 33846095368     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X154079     Document Type: Conference Paper

References (23)

1. International Osteoporosis Foundation. Osteoporosis and you. Available at: www.osteofound.org/publications/pdf/osteoporosis_and_you.pdf [last accessed 8 July 2006]
2. World Health Organization. Osteoporosis: both health organizations and individuals must act now to avoid an impending epidemic. Press release WHO/58 11 October 1999. Available at: www.who.int/inf-pr-1999/en/pr99-58.html [last accessed 4 March 2006]
3. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
4. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [Fracture Intervention Trial Research Group]. Lancet 1996;348:1535-41
5. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. J Am Med Assoc 1999;282:1344-52
6. McClung MR, Geusens P, Miller PD, et al.; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med 2001;344:333-40
7. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
8. Van Staa TP, Geusens P, Leufkens HGM, Cooper C. Persistence to bisphosphonate treatment in actual clinical practice. Osteoporosis Int 2005;16(Suppl 4):P610-Su
9. Akesson K, Beusterien K, Hebborn A, Leidy NK. Strong patient preference for once-monthly over weekly oral bisphosphonate dosing in postmenopausal osteoporosis. Osteoporosis Int 2005;16(Suppl 4):P622-Su
10. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-903
11. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis (Vertebral Efficacy with Risedronate Therapy [VERT] Study Group). Osteoporosis Int 2000;11:83-91
12. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 1998;280:2077-82
13. Emkey R. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. Med Gen Med 2004;6:6
14. Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004;20:757-64
15. Rizzoli R, Greenspan SL, Bone III G, et al. Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17:1988-96
16. Watts NB, Lindsay R, Li Z, et al. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporosis Int 2003;14:437-41
17. Silverman SL, Weiss TW, Gold DT, McHorney CA. The PREFER-US study: an evaluation of patient preferences for osteoporosis medications and their attributes. International Society for Clinical Densitometry annual meeting, 1-4 February 2006, San Diego, CA, USA [abstract 210]
18. Walliser JA, Bolge SC, Sen SS. Patients' preference for osteoporosis medications: PREFER-International. International Society for Clinical Densitometry annual meeting, 1-4 February 2006, San Diego, CA, USA [abstract 213]
19. Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 2005;27:361-76
20. Reginster JY, Felsenberg D, Cooper C, et al. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporosis Int 2006;17:159-66
21. Osterberg L, Blaschke T. Adherence to medication. New Engl J Med 2005;353:487-97
22. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16
23. Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporosis Int 2006;17:922-8